Noticias y Actividades de HighTide Therapeutics
Ejecutivos
Ver el organigrama con sus 9 ejecutivos principales
Biografías más buscadas en HighTide Therapeutics
- Liping Liu, Chief Executive Officer and Chief Science Officer
- Leigh Macconell, Chief Development Officer
- Li Yu, Vice President
Recientes movimientos de ejecutivos en HighTide Therapeutics
- Li Yu que ha sido Joint Company Secretary, pasa a ser Vice President (noticia publicada el 20 de diciembre de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en HighTide Therapeutics.
Biotecnología
HighTide Therapeutics tiene 2.351 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Genus (Reino Unido).
Popular M&A news in Biotecnología
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 4 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de HighTide Therapeutics
- News - HighTide Therapeutics, Inc.
- HighTide-HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting® 2024, Demonstrating Benefits of Berberine Ursodeoxycholate (HTD1801)
- HighTide-HighTide Therapeutics to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
- HighTide-8th Annual MASH Drug Development Summit | HighTide Therapeutics Presents Rationales for Holistic Approaches to Treating MASH and Benefits of Berberine Ursodeoxycholate (HTD1801)
- HighTide-EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxychoate (HTD1801)
- HighTide-HighTide Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
- HighTide-HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
- HighTide-HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
- HighTide-HighTide Therapeutics Invited to Present at the Abu Dhabi Global Healthcare Week Health Leaders Forum
- HighTide-HighTide Therapeutics is Invited to Present at the FII PRIORITY Asia Summit in Hong Kong: Megatrends Shaping Humanity
- View more press releases Close
Redes sociales sobre HighTide Therapeutics
- HighTide Therapeutics en Wikipedia, Google News y Yahoo Finance
- HighTide Therapeutics en LinkedIn, Twitter y YouTube
